Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.
Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende MC, Emery S, Fosdick L, Neaton J, Tavel JA, Davey RT, Lane HC; Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. Arduino RC, et al. Among authors: losso m. Clin Infect Dis. 2004 Jul 1;39(1):115-22. doi: 10.1086/421775. Epub 2004 Jun 14. Clin Infect Dis. 2004. PMID: 15206062 Clinical Trial.
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
ESPRIT Research Group; Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD. ESPRIT Research Group, et al. Among authors: losso m. HIV Med. 2007 Mar;8(2):112-23. doi: 10.1111/j.1468-1293.2007.00440.x. HIV Med. 2007. PMID: 17352768 Free article. Clinical Trial.
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
Lifson AR; INSIGHT Cause of Death Writing Group; Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J. Lifson AR, et al. HIV Clin Trials. 2008 May-Jun;9(3):177-85. doi: 10.1310/hct0903-177. HIV Clin Trials. 2008. PMID: 18547904 Free PMC article.
Factors associated with D-dimer levels in HIV-infected individuals.
Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Borges AH, et al. PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014. PLoS One. 2014. PMID: 24626096 Free PMC article.
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
ENCORE1 Study Group; Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. ENCORE1 Study Group, et al. Among authors: losso m. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12. Lancet Infect Dis. 2015. PMID: 25877963 Clinical Trial.
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial.
Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, Jessen H, Losso M, Markowitz N, Munderi P, Papadopoulos A, Shuter J, Rappoport C, Pearson MT, Finley E, Babiker A, Emery S, Duprez D; INSIGHT START Arterial Elasticity Substudy Team. Baker JV, et al. Among authors: losso m. Open Forum Infect Dis. 2016 Oct 8;3(4):ofw213. doi: 10.1093/ofid/ofw213. eCollection 2016 Oct. Open Forum Infect Dis. 2016. PMID: 27942541 Free PMC article.
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group. Aggarwal NR, et al. Clin Infect Dis. 2024 Jun 14;78(6):1490-1503. doi: 10.1093/cid/ciad780. Clin Infect Dis. 2024. PMID: 38376212 Clinical Trial.
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. Cozzi-Lepri A, et al. J Infect Dis. 2009 Sep 1;200(5):687-97. doi: 10.1086/604731. J Infect Dis. 2009. PMID: 19604043
255 results